Hims & Hers launches weight loss platform in the UK as shares face pressure due to regulatory concerns in the US.
Hims & Hers officially launched its weight loss platform in the UK on Thursday. Just a week after entering the Canadian market, the next international step is now taking place – a clear signal of the company’s growth strategy. But as management expands, investors remain nervous.
Aggressive internationalization
Table of Contents
With its launch in the UK, Hims & Hers is offering British customers access to personalized weight management programs including GLP-1 medication for the first time. After launching in Canada on December 4th, this marks the second international expansion in just a few days.
The strategy behind it is clear: the company wants to diversify its revenue base geographically and tap into markets where demand for weight loss solutions is high. The operating figures speak for themselves – in the third quarter, Hims & Hers increased sales by 49 percent to $599 million.
Should investors sell immediately? Or is it worth joining? Hims & Hers?
Regulation curbs price fantasy
Despite the expansion successes, the share price is under pressure. This is due to reports of possible legal tightening of the rules for compound GLP-1 drugs in the USA. Investors fear that stricter regulations from the FDA or the legislature could put a strain on one of the fastest-growing business areas.
The result: The stock is trading well below the $40 mark, although operational business continues to flourish. The market is pricing in a “regulatory risk” that has not yet materialized.
Analysts see upside potential
The investment bank Barclays is optimistic. Analyst Glen Santangelo set a price target of $48 on December 9th – which represents significant upside potential from current levels. However, the broad analyst consensus remains cautious and recommends “Hold” as long as regulatory uncertainty persists.
Tension between growth and regulation
Hims & Hers delivers operationally, but the stock market reacts cautiously. On Friday, the stock fell 1.48 percent to $37.21 on a trading volume of over 10 million shares. UK expansion is showing momentum, but without clarity on US regulation volatility is likely to remain high. As long as the issue of compounding rules remains unresolved, the stock will oscillate between fundamental strength and regulatory risk.
Hims & Hers share: buy or sell?! New Hims & Hers analysis from December 13th provides the answer:
The latest Hims & Hers figures speak for themselves: there is an urgent need for action for Hims & Hers shareholders. Is it worth getting started or should you sell? In the current free analysis from December 13th you will find out what to do now.
Hims & Hers: Buy or Sell? Read more here…
